alexa Abstract | A Comprehensive Drug Review on Macitentan: A Preeminent Inclusion to Pulmonary Arterial Hypertension Therapy

Research & Reviews: Journal of Pharmaceutical Quality Assurance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Macitentan is a radically novice oral orphan drug which was approved by FDA in Oct 2013 (under trade name Opsumit®). It belongs to the class of the endothelin receptor antagonist (ETRA) and is indicated for the treatment of pulmonary arterial hypertension (PAH). PAH is a chronic disorder of raising blood pressure in the artery between the aisle of heart and lung. Till the date, the disease remains incurable and possesses a poor prognosis. A ray of hope in this direction is shown by Macitentan, which has been proved beneficial in decreasing disease progression symptoms and reducing hospitalization. Phase III SERAPHIN trials clearly indicate that it improves morbidity, mortality and 6MWD data compared with other drugs of the same class. Furthermore, its use is seemingly increasing for the treatment of other cardiovascular disorders related to ET system. However, the pharmacokinetics dose adjustments of Macitentan in patients with renal or hepatic impairment are extraneous. Drug–drug interactions are occult, and one circulating pharmacologically active metabolite (ACT-132577) is omnipresent. The safety profile of Macitentan is superior to other drugs of same ETRA’s class with prolonged receptor binding properties, greater tissue penetration, hepatic safety, edema/fluid retention and easy dosing, but it is similar when the decrease in hemoglobin concentration is taken into account. Macitentan attributes, hence, are appended and revolutionary important in the therapeutic long-term treatment and a better alternative remedy for PAH. The present review thus delineates the complete drug profile of Macitentan from the data of studies carried out till date and alleges it as a sanguine future for an overall improved CVS healthcare contributor.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Dherya Bahl, Rakesh K. Jaiswal, Manzar Ahsan, Farha Bano, Monika Anand, Danish Khan, Asif Husain, Aftab Ahmad, Fahad A. Al-Abbasi, Shah Alam Khan


Hypertension, Macitentan, Receptor, Antagonist, Drug Resistance,Pulmonary vasculitis

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version